GC녹십자웰빙 announced that its domestically exclusive drug candidate RZL-012, a lipolysis agent, satisfied the primary efficacy and safety criteria in a Phase 3 trial conducted in China.
The pivotal study, run by JuveStar—a subsidiary of Fosun Pharma and the Chinese partner of Raziel Therapeutics—enrolled 480 adult patients with submental fat (double chin). The trial reported positive top‑line results.
GC녹십자웰빙 holds the exclusive rights to develop and commercialize RZL-012 in South Korea, and the successful Chinese data may support further regulatory submissions.
Research & ReportsSep 14, 2026•3 min read
GC녹십자웰빙's RZL-012 Meets Primary Endpoints in Chinese Phase 3 Trial
GC녹십자웰빙 announced that its exclusive drug candidate RZL-012 achieved primary efficacy and safety endpoints in a pivotal Phase 3 trial in China involving 480 adults with submental fat.
Compiled by the Pharmacountry team · Source: KPA News
Topics:
Ratings
(0)
(0)
(0)
(0)
(0)
Leave your rating